RT Journal Article
SR Electronic
T1 SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 1312
OP 1316
DO 10.1136/annrheumdis-2021-220461
VO 80
IS 10
A1 Simon, David
A1 Tascilar, Koray
A1 Fagni, Filippo
A1 Krönke, Gerhard
A1 Kleyer, Arnd
A1 Meder, Christine
A1 Atreya, Raja
A1 Leppkes, Moritz
A1 Kremer, Andreas E
A1 Ramming, Andreas
A1 Pachowsky, Milena L
A1 Schuch, Florian
A1 Ronneberger, Monika
A1 Kleinert, Stefan
A1 Hueber, Axel J
A1 Manger, Karin
A1 Manger, Bernhard
A1 Berking, Carola
A1 Sticherling, Michael
A1 Neurath, Markus F
A1 Schett, Georg
YR 2021
UL http://ard.bmj.com/content/80/10/1312.abstract
AB Objectives To better understand the factors that influence the humoral immune response to vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs).Methods Patients and controls from a large COVID-19 study, with (1) no previous history of COVID-19, (2) negative baseline anti-SARS-CoV-2 IgG test and (3) SARS-CoV-2 vaccination at least 10 days before serum collection were measured for anti-SARS-CoV-2 IgG. Demographic, disease-specific and vaccination-specific data were recorded.Results Vaccination responses from 84 patients with IMID and 182 controls were analysed. While all controls developed anti-SARS-CoV-2 IgG, five patients with IMID failed to develop a response (p=0.003). Moreover, 99.5% of controls but only 90.5% of patients with IMID developed neutralising antibody activity (p=0.0008). Overall responses were delayed and reduced in patients (mean (SD): 6.47 (3.14)) compared with controls (9.36 (1.85); p<0.001). Estimated marginal means (95% CI) adjusted for age, sex and time from first vaccination to sampling were 8.48 (8.12–8.85) for controls and 6.90 (6.45–7.35) for IMIDs. Significantly reduced vaccination responses pertained to untreated, conventionally and anticytokine treated patients with IMID.Conclusions Immune responses against the SARS-CoV-2 are delayed and reduced in patients with IMID. This effect is based on the disease itself rather than concomitant treatment.All data relevant to the study are included in the article or uploaded as online supplemental information. Data are under embargo by local authorities if not included into the manuscript.